INTERNATIONAL AIDS VACCINE INITIATIVE INC.
NEW YORK, NEW YORK 100042743
Top Industries (NAICS)
| NAICS Code | Obligations | Awards |
|---|---|---|
| 541714 | $70.44M | 29 |
| 541715 | $19.56M | 12 |
| 541712 | $269K | 14 |
Contract Awards
33 awards found
CGMP MANUFACTURE, FILL-FINISH, RELEASE, ANALYTICAL AND STABILITY TESTING AND STABILITY PROGRAM OF A NANOPARTICLE BASED HIV ENVELOPE VACCINE
COORDINATION AND TECHNICAL SUPPORT
COORDINATION AND TECHNICAL SUPPORT
1800010I INTERNATIONAL AIDS VACCINE INITIATIVE; OPTION 2 FY 21 $666,400
1800010I INTERNATIONAL AIDS VACCINE INITIATIVE; OPTION 2 FY 21 $666,400
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE; MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING
1800010I INTERNATIONAL AIDS VACCINE INITIATIVE; MANUFACTURE OF HUMAN FLU CHALLENGE MATERIAL
1800010I INTERNATIONAL AIDS VACCINE INITIATIVE; MANUFACTURE OF HUMAN FLU CHALLENGE MATERIAL
COORDINATION AND TECHNICAL SUPPORT
PROCESS DEVELOPMENT FOR CELL CULTURE, UPSTREAM AND DOWNSTREAM PROCESS IN PRODUCTION OF HIV-1 BIOMOLECULES
ANTIGEN-ADJUVANT FORMULATION AND CHARACTERIZATION STUDIES
CGMP MANUFACTURE, FILL-FINISH, RELEASE, ANALYTICAL AND STABILITY TESTING AND STABILITY PROGRAM OF A NANOPARTICLE BASED HIV ENVELOPE VACCINE
ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSV.G CHIMERIC VIRUS PLATFORM
PROCESS AND ASSAY DEVELOPMENT FOR CGMP PRODUCTION AND CHARACTERIZATION OF A VSV CANDIDATE
CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE; MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING
CGMP MANUFACTURE, FILL-FINISH, RELEASE, ANALYTICAL AND STABILITY TESTING AND STABILITY PROGRAM OF A NANOPARTICLE BASED HIV ENVELOPE VACCINE
CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING
NEW AWARD FOR CELL LINE OPTIMIZATION AND PRE-MASTER BANK GENERATION FOR SB 301, A VACCINE FOR HEPATITIS B VIRUS HBV
THIS TASK ORDER IS TO DEVELOP AN OPTIMIZED PHASE 1 CGMP MANUFACTURING PROCESS FOR LIPID NANOPARTICLE (LNP) FABRICATION THAT ENABLE COVALENT COUPLING OF AN HIV-1 ENV TRIMER TO THE SURFACE OF THE LNP. A NON-GMP PROCESS RUN OF DRUG PRODUCT SHALL BE PERF
1800010I INTERNATIONAL AIDS VACCINE INITIATIVE; MANUFACTURE OF HUMAN FLU CHALLENGE MATERIAL
ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSV.G CHIMERIC VIRUS PLATFORM
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
1800010I INTERNATIONAL AIDS VACCINE INITIATIVE; TO V1 OBRA--2 BASE TASK ORDER FUNDING; BIOD CAN 8470038 $60,322
THIS TASK ORDER IS TO DEVELOP AN OPTIMIZED PHASE 1 CGMP MANUFACTURING PROCESS FOR LIPID NANOPARTICLE (LNP) FABRICATION THAT ENABLE COVALENT COUPLING OF AN HIV-1 ENV TRIMER TO THE SURFACE OF THE LNP. A NON-GMP PROCESS RUN OF DRUG PRODUCT SHALL BE PERF
ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSV.G CHIMERIC VIRUS PLATFORM
1800010I IAVI BASE AWARD $810,077 FY20 CELL LINE OPTIMIZATION AND PRE-MASTER BANK GENERATION FOR SB 301, A VACCINE FOR HEPATITIS B VIRUS (HBV); TOVM20V24VB 2; IID CAN 8470036;
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
ACCELERATED VACCINE DEVELOPMENT OF A SAES-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM
ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
CGMP MANUFACTURE, FILL-FINISH, RELEASE, ANALYTICAL AND STABILITY TESTING AND STABILITY PROGRAM OF A NANOPARTICLE BASED HIV ENVELOPE VACCINE
COORDINATION AND TECHNICAL SUPPORT
Business Details
- UEI
- ZEJBC8JQM3P5
- CAGE Code
- 44YM6
- Address
- 125 BROAD ST FL 9TH
NEW YORK, NY 100042743 - Congressional District
- NY-10
- Phone
- 2128471133
Parent Company
INTERNATIONAL AIDS VACCINE INITIATIVE INC.
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov